GaBio - Georgia Bio
10/05/2026 | Press release | Distributed by Public on 10/05/2026 07:58
Georgia Life Sciences Weighs In on PBM and 340B Policy
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers' Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system.
The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients.
The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly.
GaBio - Georgia Bio published this content on October 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 05, 2026 at 13:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]